![Chemical structure of 3-[(2,4-Dimethylpyrrol-5-yl)methylidenyl]-2-indolinon, CAS 194413-58-6](https://api.angenesci.com/structure/1042/194413-58-6.png)
无数据
无数据
无数据
| CAS Number | 194413-58-6 |
| Catalog Number | AG00ACLO(AGN-PC-0QMUSV) |
| Chemical Name | 3-[(2,4-Dimethylpyrrol-5-yl)methylidenyl]-2-indolinon |
| IUPAC Name | (3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1H-indol-2-one |
| InChI | InChI=1S/C15H14N2O/c1-9-7-10(2)16-14(9)8-12-11-5-3-4-6-13(11)17-15(12)18/h3-8,16H,1-2H3,(H,17,18)/b12-8- |
| InChI Key | WUWDLXZGHZSWQZ-WQLSENKSSA-N |
| MDL Number | MFCD09763655 |
| Molecular Formula | C15H14N2O |
| Molecular Weight | 238.2845 |
| NSC Number | 696819 |
| SMILES | O=C1NC2=C(C=CC=C2)/C1=C/C3=C(C)C=C(C)N3 |
| UNII | 71IA9S35AJ |
| Synonyms | 3-(2,4-dimethylpyrrol-5-yl)methylidene-indolin-2-one,
Semaxinib,
SU 5416,
SU-5416,
SU5416,
Semaxanib,
Semaxinib,
SU5416,
SU 5416,
204005-46-9,
194413-58-6,
Semaxanib (SU5416),
Semoxind,
SU-5416,
TSU 16,
UNII-71IA9S35AJ,
VEGF Receptor 2 Kinase Inhibitor III,
(Z)-3-((3,5-dimethyl-1H-pyrrol-2-yl)methylene)indolin-2-one,
(Z)-SU 5416,
VEGFR2 Kinase Inhibitor III,
71IA9S35AJ,
CHEMBL276711,
(3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one,
3-(1-(3,5-Dimethyl-1H-pyrrol-2-yl)meth-(Z)-ylidene)-2-oxo-2,3-dihydroindole,
NSC-696819,
3-[(2,4-Dimethylpyrrol-5-yl)methylidene]-indolin-2-one,
3-((Z)-(3,5-Dimethylpyrrol-2-yl)methylene)-2-indolinone,
1,3-Dihydro-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-2H-indol-2-one,
H-Indol-2-one, 3-((3,5-dimethyl-1H-pyrrol-2-yl)methylene)-1,3-dihydro-,
InSolution™ VEGF Receptor 2 Kinase Inhibitor III,
Semaxnib,
3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one,
(3Z)-3-[(3,5-DIMETHYL-1H-PYRROL-2-YL)METHYLIDENE]-2,3-DIHYDRO-1H-INDOL-2-ONE,
Semaxanib(SU5416),
SMR000568416,
TSU-16,
SR-01000076044,
Semaxanib (USAN/INN),
Semaxanib [USAN:INN],
Sugen 5416,
methylene]-2H-indol-2-one,
(3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-1H-indol-2-one,
NCGC00094381-03,
AK174866,
AK174898,
semaxanib-su5416,
NSC 696819,
2x2m,
Semaxanib; SU5416,
S 8442,
SCHEMBL8190,
Lopac0_001110,
SCHEMBL19571,
1,3-Dihydro-3-[(3,5-dimethyl-1H-pyrrol-2-yl),
MLS001074896,
MLS001332519,
MLS001332520,
AC1NS627,
BDBM4810,
GTPL5056,
QCR-86,
3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]indolin-2-one,
CHEBI:91083,
cid_5329098,
AOB6828,
SIBNPBQTUXWRMZ-ZSOIEALJSA-N,
WUWDLXZGHZSWQZ-WQLSENKSSA-N,
HMS2234L12,
HMS3229O13,
HMS3263M22,
HMS3268J13,
HMS3648O12,
HMS3677H10,
BCP06068,
EX-A2158,
Tox21 111271,
Tox21_501110,
2033AH,
2712AH,
BS0306,
HSCI1_000303,
MFCD01940922,
NSC696819,
s2845,
SU5146,
ZINC12410091,
3-[(3,5-dimethyl-1h-pyrrol-2-yl)methylene]-1,3-dihydro-2h-indol-2-one,
AKOS015994557,
AN-3643,
CCG-205186,
CS-1225,
DB06436,
ES-0010,
LP01110,
NCGC00094381-01,
NCGC00094381-02,
NCGC00094381-04,
NCGC00094381-05,
NCGC00261795-01,
BC600544,
DA-43377,
HY-10374,
LS-83886,
QC-11357,
SC-96714,
AB0094985,
LS-193151,
RT-016226,
EU-0101110,
SW219791-1,
A12437,
D05819,
W-5403,
2H-Indol-2-one,5-dimethyl-2-pyrrolyl)methylene]-,
J-013281,
SR-01000076044-2,
SR-01000076044-8,
BRD-K63504947-001-05-5,
3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]-2-indolinone,
3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]-indolin-2-one,
3-[(3,5-Dimethyl-2H-pyrrol-2-ylidene)methyl]-1H-indol-2-ol,
(3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]indolin-2-one,
3-[(3,5-Dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro- 2H-indol-2-one,
2H-Indol-2-one, 3-((3,5-dimethyl-1H-pyrrol-2-yl)methylene)-1,3-dihydro-, (3Z)-,
2H-Indol-2-one, 3-((3,5-dimethyl-1H-pyrrol-2-yl)methylene)-1,3-dihydro-, (Z)-,
2H-Indol-2-one, 3-(3,5-dimethyl-1H-pyrrol-2-yl)methylene)- 1,3-dihydro-, (Z)-,
3-[1-(3,5-dimethyl-1h-pyrrol-2-yl)-meth-(z)-ylidene]-2-oxo-2,3-dihydro-indole,
Romiplostim,
InSolution&trade,
Semaxanib [INN],
Semaxanib (u-5416),
D01PZD,
D04ADG,
D0QY0V,
C15H14N2O,
CS-AD-00525,
C15-H14-N2-O,
CID5329098,
A3847,
3-(2,4-dimethylpyrrol-5-yl)methylidene-indolin-2-one,
C116890,
C549241,
3-((2,4-dimethylpyrrol-5-yl)methylidenyl)-2-indolinone,
SU 5416, 98%, a VEGFR2/Flk1 inhibitor - 100MG 100mg,
2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-,
2H-Indol-2-one, 3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylene]-1,3-dihydro-, (3Z)-,
267639-76-9,
|
| Complexity | 377 |
| Compound Is Canonicalized | Yes |
| Covalently-Bonded Unit Count | 1 |
| Defined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 1 |
| Exact Mass | 238.111g/mol |
| Formal Charge | 0 |
| Heavy Atom Count | 18 |
| Hydrogen Bond Acceptor Count | 1 |
| Hydrogen Bond Donor Count | 2 |
| Isotope Atom Count | 0 |
| Molecular Weight | 238.29g/mol |
| Monoisotopic Mass | 238.111g/mol |
| Rotatable Bond Count | 1 |
| Topological Polar Surface Area | 44.9A^2 |
| Undefined Atom Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| XLogP3 | 2.5 |
| Symbol: | |
| Hazard Class | |
| Hazard statements | H317-H319 |
| Packing Group | |
| Precautionary statements | P280-P305+P351+P338 |
| UN Code |
| Chemical Name: | Batch Number: | |
| Chemical Structure: | CAS Registry No: | |
| Product ID: | ||
| Manufacture Date: | ||
| Storage Temperature: | ||
| Formula: | ||
| Molecular Weight: | ||
| Quantity: |
| Test: | Result: |

